Literature DB >> 30892097

Infection prevention and control in cystic fibrosis: a systematic review of interventions.

Nicola J Rowbotham1, Sally C Palser1, Sherie J Smith1, Alan R Smyth1.   

Abstract

INTRODUCTION: Cystic fibrosis is a life-limiting genetic condition characterized by recurrent pulmonary infection. Acquisition of infection can occur from environmental reservoirs, person-to-person transmission and from the healthcare environment. Primary prevention of infections through infection prevention and control measures is an important strategy in cystic fibrosis care. Areas covered: Here we present a systematic review of the evidence base around infection prevention and control in cystic fibrosis. We found 36 studies and 7 guidelines that met our inclusion criteria. Strategies covered include cohort segregation, individual segregation, hand hygiene, facemasks, combination strategies, equipment strategies, and adherence. Quality of evidence overall was deemed low or very low. Most guideline recommendations have little or no evidence to support them. Expert opinion: Although low quality, there is an abundance of evidence suggesting segregation is beneficial in reducing pathogen spread. Undertaking high-quality studies may, therefore, be ethically challenging. Large-scale registry studies may provide a better strategy for answering questions on the efficacy of infection control policy. With the rise of antibiotic resistance, effective eradication of cystic fibrosis pathogens is becoming more difficult so primary prevention through infection control will become increasingly important over the coming years.

Entities:  

Keywords:  Cystic Fibrosis; infection prevention and control; systematic review

Mesh:

Year:  2019        PMID: 30892097     DOI: 10.1080/17476348.2019.1595594

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  3 in total

Review 1.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

2.  Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis.

Authors:  N J Rowbotham; S J Smith; Z C Elliott; P A Leighton; O C Rayner; R Morley; A R Smyth
Journal:  Res Involv Engagem       Date:  2019-08-20

3.  International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives.

Authors:  June K Marthin; Jane S Lucas; Mieke Boon; Carmen Casaulta; Suzanne Crowley; Damien M S Destouches; Ernst Eber; Amparo Escribano; Eric Haarman; Claire Hogg; Bernard Maitre; Gemma Marsh; Vendula Martinu; Antonio Moreno-Galdó; Huda Mussaffi; Heymut Omran; Petr Pohunek; Bernhard Rindlisbacher; Phil Robinson; Deborah Snijders; Woolf T Walker; Panayiotis Yiallouros; Helle Krogh Johansen; Kim G Nielsen
Journal:  ERJ Open Res       Date:  2021-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.